SGN-15

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2005
01220012005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
PURPOSE Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced… (More)
Is this relevant?
2005
2005
Effective antibody-drug conjugates (ADC) combine high drug-linker stability in circulation and efficient intratumoral release of… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2004
2004
7039 Background: Docetaxel (Doc) remains the only FDA approved second line chemotherapy for NSCLC, but response rates and… (More)
Is this relevant?
2003
2003
OBJECTIVE The SGN-15 monoclonal antibody-doxorubicin immunoconjugate is toxic to Lewis(Y) antigen-expressing cells and is… (More)
Is this relevant?
Review
2001
Review
2001
Seattle Genetics is developing SGN-15 (BMS-182248, BR96-DOX), a monoclonal antibody-doxorubicin conjugate licensed from Bristol… (More)
Is this relevant?
Review
2001
Review
2001
Seattle Genetics is developing SGN-10 (BR96-SCIT), a single-chain immunotoxin (SCIT) under license from Bristol-Myers Squibb (BMS… (More)
Is this relevant?